Megaphone icon ETF Database is now VettaFi. Read More >
ETFdb Logo
ETFdb Logo
  • ETF Database
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Free Cash Flow
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Portfolio Strategies
    • Retirement Income
    • Thematic Investing
    • Volatility Resource
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. Verve Therapeutics Shares Up 84%; ARKG Offers Exposure
Disruptive Technology Channel
Share

Verve Therapeutics Shares Up 84%; ARKG Offers Exposure

Elle CarusoJul 26, 2022
2022-07-26

The biotech sector can offer unique opportunities and strong returns to investors willing to stomach the volatility heightened by the current economic environment.

Shares of Verve Therapeutics (VERV) traded up 22% last Tuesday after the company’s recent announcement that it dosed its first human patient with an investigational in vivo base-editing medicine, VERVE-101, as a potential treatment for heterozygous familial hypercholesterolemia, according to recent commentary from ARK Invest. 

The treatment from the Cambridge, Massachusetts-headquartered company could offer an alternative for hypercholesterolemia patients who have difficulty managing the side effects of statins and other therapeutic options. Founded by world-renowned experts in cardiovascular medicine, human genetics, and gene editing, Verve Therapeutics develops transformative once-and-done therapies for coronary heart disease, according to ARK.

Shares of Verve Therapeutics are up over 83% over a one-month period, according to YCharts. Over a five-day period, shares are down over 7%, but they are rebounding and up nearly 1% in mid-day trading on Tuesday. 

Investors can get exposure to Verve Therapeutics with the ARK Genomic Revolution ETF (ARKG A-). ARKG is an actively managed equity strategy that aims to provide exposure to DNA sequencing technology, gene editing, CRISPR, therapeutics, agricultural biology, and molecular diagnostics. 

Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their businesses, according to the firm.

The fund’s top holdings as of July 26 include Exact Sciences Corp. (EXAS, 7.42%), Teladoc Health Inc. (TDOC, 5.56%), Ionis Pharmaceuticals Inc. (IONS, 5.30%), CRISPR Therapeutics AG (CRSP, 4.78%), and Signify Health Inc. – Class A (SGFY, 4.70%), according to the fund’s website.

ARKG typically holds between 40 and 60 securities and charges an expense ratio of 75 basis points. 

For more news, information, and strategy, visit our Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

ETF Education Channel

How to Allocate Commodities in Portfolios

Tom LydonApr 26, 2022
2022-04-26

A long-running debate in asset allocation circles is how much of a portfolio an investor should...

Core Strategies Channel

Why ETFs Experience Limit Up/Down Protections

Karrie GordonMay 13, 2022
2022-05-13

In a digital age where information moves in milliseconds and millions of participants can transact...

}
X